A SINGLE ARM, PROSPECTIVE, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF ISAVUCONAZOLE FOR PRIMARY TREATMENT OF CHINESE PATIENTS WITH INVASIVE FUNGAL DISEASE (IFD) CAUSED BY ASPERGILLUS SPECIES OR OTHER FILAMENTOUS FUNGI
Latest Information Update: 22 Jul 2025
At a glance
- Drugs Isavuconazonium (Primary)
- Indications Invasive bronchopulmonary aspergillosis; Mycoses
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 10 Jul 2025 Status changed from active, no longer recruiting to completed.
- 05 Feb 2025 Planned End Date changed from 27 Jun 2025 to 26 Apr 2025.
- 05 Feb 2025 Planned primary completion date changed from 27 Jun 2025 to 26 Apr 2025.